key: cord-0801245-z9wmar5k authors: Du, Wenjuan; Hurdiss, Daniel L.; Drabek, Dubravka; Mykytyn, Anna Z.; Kaiser, Franziska K.; González-Hernandez, Mariana; Muñoz-Santos, Diego; Lamers, Mart M.; van Haperen, Rien; Li, Wentao; Drulyte, Ieva; Wang, Chunyan; Sola, Isabel; Armando, Federico; Beythien, Georg; Ciurkiewicz, Malgorzata; Baumgärtner, Wolfgang; Guilfoyle, Kate; Smits, Tony; van der Lee, Joline; van Kuppeveld, Frank J.M.; van Amerongen, Geert; Haagmans, Bart L.; Enjuanes, Luis; Osterhaus, Albert D.M.E.; Grosveld, Frank; Bosch, Berend-Jan title: An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants date: 2022-02-17 journal: bioRxiv DOI: 10.1101/2022.02.17.480751 sha: fa3a2e10790a78782510c7e06fb986b9faf9b96b doc_id: 801245 cord_uid: z9wmar5k The ongoing evolution of SARS-CoV-2 has resulted in the emergence of Omicron, which displays striking immune escape potential. Many of its mutations localize to the spike protein ACE2 receptor-binding domain, annulling the neutralizing activity of most therapeutic monoclonal antibodies. Here we describe a receptor-blocking human monoclonal antibody, 87G7, that retains ultrapotent neutralization against SARS-CoV-2 variants including the Alpha, Beta, Gamma, Delta and Omicron (BA.1/BA.2) Variants-of-Concern (VOCs). Structural analysis reveals that 87G7 targets a patch of hydrophobic residues in the ACE2-binding site that are highly conserved in SARS-CoV-2 variants, explaining its broad neutralization capacity. 87G7 protects mice and/or hamsters against challenge with all current SARS-CoV-2 VOCs. Our findings may aid the development of sustainable antibody-based strategies against COVID-19 that are more resilient to SARS-CoV-2 antigenic diversity. One sentence summary A human monoclonal antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of the RBR, the epitope-paratope region was poorly resolved. To improve the interpretation of the 154 87G7 binding site, focused refinement was performed on the Fab-RBD region of the density map, 155 which improved the local resolution sufficiently to resolve the bulky sidechains which make up the 156 majority of the epitope-paratope interface ( Figure S2h) . Consistent with our BLI data, the 87G7 affinity and/or enable antibody escape (25, 27, 35) . We measured the neutralization potential of 219 87G7 against pseudoviruses carrying S proteins with single site RBD mutations found in 220 VOCs/VOIs. In contrast to REGN10933, 87G7 displayed potent neutralization against all S 221 mutations tested, which is consistent with the ability of 87G7 to retain potent neutralization against 222 the SARS-CoV-2 variants (Figure 3b ) (25) . 223 224 87G7 provides in vivo protection from challenge with D614G and SARS-CoV-2 variants 225 The in vivo protection capacity of 87G7 against SARS-CoV-2 challenge was first evaluated using 226 the K18-hACE2 transgenic mice model. To assess prophylactic activity, mice were 227 intraperitoneally injected with 87G7 (10 mg/kg body weight) or an IgG1 isotype control (10 mg/kg) 228 and challenged intranasally 16 hours later with 10 5 PFU of SARS-CoV-2 using the D614G strain 229 and Alpha, Beta, Gamma or Delta VOCs. To assess therapeutic activity, 87G7 or isotype control 230 was administered (10 mg/kg) at day 1 after challenge with D614G. Mice were scored for weight 231 loss and lungs were collected at day five after challenge for quantification of lung antigen levels 232 and infectious virus. Animals in isotype-treated groups started losing weight after two days (Alpha 233 and Gamma), three days (D614G and Beta) or four days (Delta) post-infection. 87G7-treated 234 animals however were protected from weight loss upon challenge, consistent with the observed 235 reduction in lung antigen levels at day five after challenge in these mice compared to isotype-236 control treated animals (Figure 4a and b) . The amount of live virus detected in the lung 237 homogenates decreased by at least one to three orders of magnitude compared to mice receiving 243 Protective efficacy by 87G7 was further evaluated in a hamster model of SARS-CoV-2 infection. 244 Syrian hamsters were administered intraperitoneally with 87G7 (10 mg/kg or 20 mg/kg for 245 Omicron-challenged hamsters) or an IgG1 isotype control (10 mg/kg or 20 mg/kg for Omicron-246 challenged hamsters), 24 h before or 12 h after intranasal challenge with 10 4 TCID50 of the 247 D614G SARS-CoV-2, Gamma, Delta or Omicron variant. 87G7 administration reduced infectious 248 virus titers in the lungs of most animals in all groups to almost undetectable levels (Figure 5a) . 249 Preventive treatment with 87G7 reduced infectious virus titers in the nasal cavity of the D614G-, 250 Gamma-and Delta-and Omicron-challenged hamsters by approximately 1-2 logs compared to 251 isotype control antibody treated groups. Histopathological analysis of lung sections from 87G7-treated hamsters showed a markedly reduced number of lesions for all tested variants compared 253 to isotype-treated animals, whereas this pathological difference in the nasal cavity was less 254 prominent ( Figure 5b ). In addition, prophylactic treatment with 87G7 clearly resulted in a notable 255 reduction in antigen expression levels both in the lung and nasal cavity (Figure 5c ). Therapeutic 256 treatment with 87G7 of the D614G-challenged hamsters significantly reduced infectious virus 257 titers detected in the lungs (>3 log reduction) and nose (approximately 1 log reduction) at day 4 258 after challenge, and lowered lesions and antigen levels in these respiratory tissues (Figure 5d-f) . 259 Overall, the ACE2-blocking 87G7 exhibits broad and potent neutralizing activity and protects 260 against challenge with ancestral SARS-CoV-2 and key variants of concern, including Omicron 261 that is on its way to become the dominant lineage worldwide. L18F T19I T19R T20N L24S ∆25-27 P26S A67V ∆69/70 G75V T76I D80A T95I D138Y G142D ∆143-145 Wuhan-Hu-1 Table S3-S5) . 356 The mean values ± SEM of all data points were shown. the original respiratory specimens. For Omicron, the S1 region of spike was not covered well due 376 to primer mismatches. Therefore, the S1 region of the original respiratory specimen and passage (Table S2) . immunohistochemistry. Related to Figure 5C and 5F. Emerging SARS-CoV-2 variants of concern evade humoral immune 659 responses from infection and vaccination mRNA-based COVID-19 vaccine boosters induce neutralizing 661 immunity against SARS-CoV-2 Omicron variant Four SARS-CoV-2 vaccines induce quantitatively different antibody 663 responses against SARS-CoV-2 variants. medRxiv The Omicron variant is highly resistant against antibody-mediated 665 neutralization: Implications for control of the COVID-19 pandemic SARS-CoV-2 neutralizing antibody structures inform therapeutic 667 strategies Antibodies elicited by mRNA-1273 vaccination bind more broadly to the 669 receptor binding domain than do those from SARS-CoV-2 infection Mapping mutations to the SARS-CoV-2 RBD that escape binding by 672 different classes of antibodies Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic 674 shift Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 Structural basis of SARS-CoV-2 Omicron immune evasion and receptor 678 engagement Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies Considerable escape of SARS-CoV-2 Omicron to antibody neutralization SARS-CoV-2 Omicron: evasion of potent humoral responses and 684 resistance to clinical immunotherapeutics relative to viral variants of concern. medRxiv An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes 687 neutralization by several therapeutic monoclonal antibodies Omicron-B.1.1.529 leads to widespread escape from neutralizing 689 antibody responses Antibody Evasion Properties of SARS-CoV-2 Omicron Sublineages. bioRxiv LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. 693 bioRxiv Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational 695 escape seen with individual antibodies Structure-based design of prefusion-stabilized SARS-CoV-2 spikes Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain 699 Reveals Constraints on Folding and ACE2 Binding A vaccine-induced public antibody protects against SARS-CoV-2 and 701 emerging variants Ultrapotent human antibodies protect against SARS-CoV-2 challenge via 703 multiple mechanisms Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly 705 emerged mutational variants Genetic and structural basis for SARS-CoV-2 variant neutralization by a two A highly potent antibody effective against SARS-CoV-2 variants of concern Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 711 variants Low-dose in vivo protection and neutralization across SARS-CoV-2 variants 713 by monoclonal antibody combinations Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and 715 serum antibody neutralization REGN-COV2, a Neutralizing Antibody Cocktail Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody 719 Time to knock monoclonal antibodies off the platform for 721 patients hospitalised with COVID-19. The Lancet Infectious Diseases Divergent SARS CoV-2 Omicron-specific T-and B-cell 723 responses in COVID-19 vaccine recipients A conserved immunogenic and vulnerable site on the coronavirus spike protein 725 delineated by cross-reactive monoclonal antibodies A human monoclonal antibody blocking SARS-CoV-2 infection Towards a solution to MERS: protective human monoclonal antibodies 729 targeting different domains and functions of the MERS-coronavirus spike glycoprotein. Emerg. 730 Microbes Infect Studies in humanized mice and convalescent humans yield a SARS-CoV-2 Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV 734 antibody A highly conserved cryptic epitope in the receptor binding domains of SARS-736 New tools for automated high-resolution cryo-EM structure determination in 738 RELION-3. eLife cryoSPARC: algorithms for rapid 740 unsupervised cryo-EM structure determination Non-uniform refinement: adaptive regularization improves 742 single-particle cryo-EM reconstruction UCSF Chimera--a visualization system for exploratory research and 744 analysis DeepEMhancer: a deep learning solution for cryo-EM volume post-746 processing Proceedings of the Practice and Experience in Advanced Research Computing 749 2017 on sustainability, success and impact Coot: model-building tools for molecular graphics SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 755 receptor The Phyre2 web portal 757 for protein modeling, prediction and analysis Structural analysis of glycoproteins: building N-linked glycans with Use of knowledge-based restraints in phenix.refine to improve 761 macromolecular refinement at low resolution MolProbity: all-atom structure validation for macromolecular crystallography EMRinger: side chain-directed model and map validation for 3D cryo-766 electron microscopy Privateer: software for the conformational validation of carbohydrate structures Carbohydrate anomalies in the PDB Inference of macromolecular assemblies from crystalline state LigPlot+: Multiple Ligand-Protein Interaction Diagrams for 774 Drug Discovery Meeting modern challenges in visualization and 776 analysis Collaboration gets the most out of software Approaches to Evaluate Lung 779 Inflammation in Translational Research SARS-CoV-2 Omicron variant causes mild pathology in the upper and lower 781 respiratory tract of Syrian golden hamsters Vasculitis and Neutrophil Extracellular Traps in Lungs of Golden Syrian We thank Caroline Schütz, Julia Baskas, Jana-Svea Harre, Vera Nijman,